Zolpidem use is independently associated with an increased risk of incident arrhythmia, particularly tachyarrhythmias such as paroxysmal tachycardia and atrial flutter. Clinicians should incorporate cardiac risk assessment into their prescribing decisions and consider periodic monitoring for high-risk patients. Study limitations include the observational design and the unavailability of granular dosage data.
Chen et al. (Tue,) studied this question.